BARD GEESAMAN

Bard Geesaman stands as a distinguished Managing Partner at MPM Capital, a premier venture capital firm renowned for its pioneering investments in the life sciences sector. At MPM Capital, Mr. Geesaman plays a critical role in the firm's strategy of identifying, founding, and building transformative biotechnology companies from inception. His leadership is instrumental in guiding investments towards innovative therapeutic platforms and drug discovery initiatives that promise to address significant unmet medical needs.

Mr. Geesaman's investment focus is deeply rooted in the biotechnology landscape, encompassing a broad spectrum of areas from novel drug discovery and development to advanced therapeutic modalities. He is particularly adept at recognizing early-stage scientific breakthroughs with the potential to evolve into robust clinical pipelines. His work at MPM Capital often involves a hands-on approach, collaborating closely with scientific founders and management teams to translate cutting-edge research into viable companies capable of delivering life-changing medicines.

Prior to his tenure as a Managing Partner at MPM Capital, Bard Geesaman cultivated an impressive career marked by significant contributions across both venture capital and operational roles within the biotech industry. He earned his Master of Business Administration from Harvard Business School and holds a Bachelor of Arts from Yale University, providing him with a strong foundation in both business acumen and scientific understanding. This dual perspective has been invaluable in his ability to evaluate complex scientific propositions and guide their commercial development. His extensive background has equipped him with a unique insight into the challenges and opportunities inherent in bringing novel therapies to market.

Throughout his career, Mr. Geesaman has been instrumental in the creation and growth of numerous successful biotechnology companies. His notable investments and company-building efforts include his involvement with Orna Therapeutics, a leader in circular RNA technology; ReNAgade Therapeutics, focused on RNA medicines; and ElevateBio, a company dedicated to cell and gene therapy manufacturing and development. He also played a key role in Cullinan Oncology, a company developing targeted oncology treatments, and TCR2 Therapeutics, which was acquired by Adaptimmune, showcasing his ability to identify and nurture companies through successful exits. These examples underscore his strategic vision and commitment to fostering innovation that translates into tangible patient benefits.

Bard Geesaman's dedication to advancing medical science through strategic investment and company building has solidified his reputation as a key figure in the biotechnology venture capital community. His work at MPM Capital continues to drive the development of next-generation therapies, making a profound impact on the future of healthcare.